Regression discontinuity was a valid design for dichotomous outcomes in three randomized trials

J Clin Epidemiol. 2018 Jun:98:70-79. doi: 10.1016/j.jclinepi.2018.02.015. Epub 2018 Feb 24.

Abstract

Objective: Regression discontinuity (RD) is a quasi-experimental design that may provide valid estimates of treatment effects in case of continuous outcomes. We aimed to evaluate validity and precision in the RD design for dichotomous outcomes.

Study design and setting: We performed validation studies in three large randomized controlled trials (RCTs) (Corticosteroid Randomization After Significant Head injury [CRASH], the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO], and PROspective Study of Pravastatin in elderly individuals at risk of vascular disease [PROSPER]). To mimic the RD design, we selected patients above and below a cutoff (e.g., age 75 years) randomized to treatment and control, respectively. Adjusted logistic regression models using restricted cubic splines (RCS) and polynomials and local logistic regression models estimated the odds ratio (OR) for treatment, with 95% confidence intervals (CIs) to indicate precision.

Results: In CRASH, treatment increased mortality with OR 1.22 [95% CI 1.06-1.40] in the RCT. The RD estimates were 1.42 (0.94-2.16) and 1.13 (0.90-1.40) with RCS adjustment and local regression, respectively. In GUSTO, treatment reduced mortality (OR 0.83 [0.72-0.95]), with more extreme estimates in the RD analysis (OR 0.57 [0.35; 0.92] and 0.67 [0.51; 0.86]). In PROSPER, similar RCT and RD estimates were found, again with less precision in RD designs.

Conclusion: We conclude that the RD design provides similar but substantially less precise treatment effect estimates compared with an RCT, with local regression being the preferred method of analysis.

Keywords: Causal inference; Local logistic regression; Logistic regression; Polynomials; Quasi-experimental trials; Regression discontinuity design; Restricted cubic splines; Trial design.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Causality
  • Confidence Intervals
  • Coronary Occlusion / drug therapy*
  • Coronary Occlusion / mortality
  • Craniocerebral Trauma / drug therapy*
  • Craniocerebral Trauma / mortality
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Logistic Models
  • Middle Aged
  • Odds Ratio
  • Pravastatin / therapeutic use
  • Randomized Controlled Trials as Topic*
  • Regression Analysis
  • Reproducibility of Results
  • Streptokinase / therapeutic use
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome*
  • Vascular Diseases / mortality
  • Vascular Diseases / prevention & control*
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Anticholesteremic Agents
  • Fibrinolytic Agents
  • Streptokinase
  • Tissue Plasminogen Activator
  • Pravastatin